Chinese Journal of Cancer Research

, Volume 20, Issue 2, pp 77–84

Anti-tumor action and clinical application of proteasome inhibitor

Authors

  • Yong-ming Zhou周咏明
    • Department of hematology, The Affiliated HospitalWuhan University of Science and Technology
  • Mei-xia Yu余美霞
    • Department of hematology, The Affiliated HospitalWuhan University of Science and Technology
  • Hui Long龙辉
    • Department of hematology, The Affiliated HospitalWuhan University of Science and Technology
    • Stem Cell Center, Union Hospital, Tongji Medical CollegeHuazhong University of Science and Technology
Review

DOI: 10.1007/s11670-008-0077-1

Cite this article as:
Zhou, Y., Yu, M., Long, H. et al. Chin. J. Cancer Res. (2008) 20: 77. doi:10.1007/s11670-008-0077-1

Abstract

Ubiquitin-proteasome pathway mediates the degradation of cell protein, and cell cycle, gene translation and expression, antigen presentation and inflammatory development. Proteasome inhibitor can inhibit growth and proliferation of tumor cell, induce apoptosis and reverse multipledrug resistance of tumor cell, increase the sensitivity of other chemotherapeutic drugs and radiotherapy, and is a novel class of potent anti-tumor agents.

Key words

Proteasome inhibitorUbiquitin-proteasome pathwayTumor

CLC number

R963

Copyright information

© Chinese Anti-Cancer Association and Springer-Verlag GmbH 2008